John A. Fry MD, FACC, FSCAI

Interventional Cardiology
Complex and High Risk PCI
Preventive Cardiology
Tweets =my own

[John A. Fry MD, FACC, FSCAI @JohnAFryMD]

@Allison_Dupont @SVRaoMD Agree! Remember the abrupt closure rates of PTCA prior to availability of coronary stents? New platforms promising but let’s wait and see what the science says

[FRANCESCO BURZOTTA @BURZOTTA_F]

After 2 years of work, the 🇪🇺 consensus on #IVUS  #OCT use in #LM #PCI is now published in #EHJ. Great international  collaboration coordinated by #EBC and #EAPCI !!!
It includes fantastic practical images that can be hung on the walls of all cath labs…
https://t.co/2TbBTIoMxu

[Zille Huma @Zill_cardio]

Coronary Computed Tomography Angiography to Guide Percutaneous Coronary Intervention: Expert Opinion from a SCAI/SCCT Roundtable | @MyJSCAI

#whyCT #VirtualPCI @SCAI
#mustread
https://t.co/7AEdGaJigo

[John A. Fry MD, FACC, FSCAI @JohnAFryMD]

London Marathon 2026 results: Sabastian Sawe makes history with first competitive sub-two-hour marathon - BBC Sport https://t.co/grBSa0xFZ4

[MyJSCAI @MyJSCAI]

🗣️📢Contralateral Radial Access for IMA Graft #Angiography Case Series featured at #SCAI2026 now in #JSCAI📚

A simplified guide-extension technique enabled safe, successful internal mammary artery graft angiography from contralateral #radialaccess in all cases.

🔗 https://t.co/L6OrKLH8dN

@DocSavageTJU

[MyJSCAI @MyJSCAI]

🗣️Pulse Oximetry vs #SaO₂ During Right Heart Cath

Pulse oximetry frequently overestimated arterial oxygen saturation during right heart catheterization, significantly altering Fick-derived hemodynamics and resistance calculations. Important workflow implications, now in #JSCAI and presented at #SCAI2026.

🔗 https://t.co/YyswFC11zD

#Hemodynamics #RightHeartCath #PulmonaryHypertension

[John A. Fry MD, FACC, FSCAI @JohnAFryMD]

Shock Initiative Demonstrates Over 70% Survival in Patients with Cardiogenic Shock, with Improved Outcomes in Stage E Shock at Centers with Escalation Capabilities | SCAI https://t.co/kfrfFmWoFk

[American Heart Association @American_Heart]

The American Heart Association mourns the passing of the legendary cardiologist Eugene Braunwald, M.D., widely recognized as one of the most influential figures in the history of cardiovascular medicine. Over seven decades, his work reshaped the understanding and treatment of heart disease, leading many to call him the father of modern cardiology.

Braunwald was a lifelong contributor to the American Heart Association, helping advance its research and scientific mission, and was honored with some of the Association’s highest honors for his lasting influence on cardiovascular care and research. His influence extended well beyond his own discoveries, as generations of Association‑supported investigators, clinicians and academic leaders were trained by Braunwald or guided by the clinical trial standards and mentorship models he helped establish.

https://t.co/ieZuHYMyOP

[John A. Fry MD, FACC, FSCAI @JohnAFryMD]

@DrJayMohan Grew up with this wire! Everyone’s workhorse back in the day. Good product. I never use it now. Much better options available from Asahi as well as the Terumo Runthrough

[Circulation @CircAHA]

#SimPub #ACC26 HEPARIN STEMI RCT: Pre-hospital UFH at first medical contact improved pre-PCI TIMI 2-3 flow without excess bleeding. Supports routine prehospital anticoagulation in STEMI referred for primary PCI. @DaniloFrancoMD https://t.co/Y1hamaaLuI

[American College of Cardiology @ACCinTouch]

SMART-DECISION: Discontinuing beta-blocker therapy was found to be noninferior to continuing the therapy among stable, low-risk patients who took it for at least one year following a #cvMI.

Get the latest insights from the #ACC26 LBCT: https://t.co/Q4BGcET3E3

[NEJM @NEJM]

Presented at #ACC26:

Among patients with a preserved ejection fraction at least 1 year after myocardial infarction, stopping beta-blockers was noninferior to continuing therapy with respect to major clinical outcomes. Full SMART-DECISION trial results: https://t.co/dZS03RaTcA

@ACCinTouch

[NEJM @NEJM]

Original Article: Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease (Ez-PAVE trial) https://t.co/CTWl7ZhKAK

Editorial: Paving the Road toward Targeted Lipid Lowering https://t.co/TDyNTho3Co

#ACC26 | @ACCinTouch

[NEJM @NEJM]

Presented at #ACC26:

In the ALL-RISE trial, FFRangio (fractional flow reserve derived from angiography) was noninferior to pressure-wire–guided assessment in reducing risk among patients with intermediate coronary stenosis. Full trial results: https://t.co/rAdXWtlS7X

Editorial: Toward Broader Adoption of Coronary Physiological Assessment https://t.co/9MEfaDg9IO

@ACCinTouch

[JACC Journals @JACCJournals]

In patients with symptomatic single-vessel chronic total occlusion, percutaneous coronary intervention for coronary chronic total occlusion (CTO PCI) improves angina beyond placebo.

Get the details in #JACC: https://t.co/yX0FDuSOjl #ACC26 #PCI #CTO @dr_skhan1

[C. Michael Gibson MD @CMichaelGibson]

MOMENTUM study revealed high prevalence of hypercortisolism & hyperaldosteronism in U.S. resistant HTN patients, suggesting the importance of screening for both. #ACC26 View Slides Here: https://t.co/4f75jGEnXc

[NEJM @NEJM]

Presented at #ACC26:

Among patients with atherosclerotic cardiovascular disease, targeting an LDL cholesterol level below 55 mg per deciliter led to a lower 3-year risk of cardiovascular events than targeting a level below 70 mg per deciliter. Full Ez-PAVE trial results: https://t.co/q0vNdAoJJL

Editorial: Paving the Road toward Targeted Lipid Lowering https://t.co/zUwmo0r0n4

@ACCinTouch

[American College of Cardiology @ACCinTouch]

#ACC26: 🆕 Insights from the CHAMPION-AF trial

Device-based LAA closure was comparable to NOAC therapy in reducing the combined rate of death from CV causes, stroke, or systemic embolism at 3️⃣ years in pts w/ #AFib who were candidates for #cvCoag.

More: https://t.co/Q0r99ZgeIf

[C. Michael Gibson MD @CMichaelGibson]

HARP study: OCT + CMR identified an underlying cause in 79% of MINOCA presentations; clinical factors had limited utility in predicting imaging abnormalities. #ACC26 Download slides here: https://t.co/hS5rnSdPmm

[C. Michael Gibson MD @CMichaelGibson]

STEMI-DTU trial: Combination of the Impella CP plus device a 30-minute delay to PCI did not reduce infarct size vs. immediate PCI in patients with anterior STEMI without shock. #ACC26 View slides here: https://t.co/yzmg7CwT0k